Dietrich Stber - Basilea Pharmaceutica Head Services
| BPMUF Stock | USD 44.45 0.00 0.00% |
Insider
Dietrich Stber is Head Services of Basilea Pharmaceutica AG
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Schaible | Fortress Biotech Pref | N/A | |
| Michael Schickler | Purple Biotech | 66 | |
| Michael Esq | Fortress Biotech Pref | 57 | |
| Michael Breen | GT Biopharma | 61 | |
| Kathryn Andrews | Alterity Therapeutics | 57 | |
| BSc FRCPC | Inhibikase TherapeuticsInc | N/A | |
| David Jin | Fortress Biotech Pref | 33 | |
| Rudolph Tanzi | Alterity Therapeutics | 65 | |
| David MD | Alterity Therapeutics | 63 | |
| Joseph CPA | Inhibikase TherapeuticsInc | 62 | |
| Nir Livneh | Purple Biotech | 45 | |
| Ido Morpurgo | Purple Biotech | 51 | |
| MPH MBA | GT Biopharma | N/A | |
| Steven Targum | Alterity Therapeutics | N/A | |
| Marcus Schindler | Novo Nordisk AS | 58 | |
| Henrik Poulsen | Novo Nordisk AS | 53 | |
| Monique Carter | Novo Nordisk AS | 51 | |
| Manu Ohri | GT Biopharma | 69 | |
| Samuel Berry | Fortress Biotech Pref | N/A | |
| PharmD MBA | GT Biopharma | N/A | |
| Robert Cherny | Alterity Therapeutics | N/A | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Rinderknecht, Member of the Board of Directors | ||
| Marc Engelhardt, Member of the Management, Chief Medical Officer | ||
| Martin Nicklasson, Chairman of the Board of Directors | ||
| Domenico Scala, Member of the Board of Directors | ||
| Guenter Ditzinger, CTO, Member of the Management Committee | ||
| Marc MD, Chief Officer | ||
| Barbara Zink, Head - Corporate Development | ||
| Nicole Onetto, Member of the Board of Directors | ||
| Heidi McDaid, Head of Global HR | ||
| Peer Schroder, Head Relations | ||
| Ingrid HeinzeKrauss, Member of the Management Committee, CTO | ||
| Dietrich Stber, Head Services | ||
| HansBeat Guertler, Member of the Board of Directors | ||
| Peer Schroeder, Head of Corporate Communications & Investor Relations | ||
| Lutz Wevelsiep, Head Affairs | ||
| Daniel Lew, Member of the Board of Directors | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Donato Spota, CFO | ||
| Achim Kaufhold, Member of the Management Committee, Chief Medical Officer | ||
| Ronald Scott, CEO | ||
| Alf Nicklasson, Member of the Board of Directors | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| Anne Stehlin, Member of the Management Board, Head of Global Quality Management | ||
| Thomas Werner, Member of the Board of Directors | ||
| Laurenz Kellenberger, Chief Scientific Officer | ||
| Steven Skolsky, Member of the Board of Directors |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
| 0.83 | CSLLY | CSL | PairCorr |
| 0.81 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.79 | TLK | Telkom Indonesia Tbk Earnings Call This Week | PairCorr |
| 0.75 | CMXHF | CSL Limited | PairCorr |
| 0.73 | TLKMF | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |